INVICTUS MD STRATEGIES CORP.’s (TSXV: IMH; OTC: IVITF; FRA: 8IS1) Acreage Pharms Ltd. is pleased to announce it has acquired 23 new cannabis strains. This marks an important step in Acreage Pharms’ march towards full-capacity cannabis production and sale this year.
“The acquisition of these strains broadens Acreage Pharms strain variety in preparation for the recreational market,” said Dan Kriznic, Chairman and CEO of Invictus. “The timing is ideal, as our Phase 2 expansion includes 11 new flowering rooms, all of which will be needed to accommodate this welcome and dramatic expansion of strains.”
The collaboration allows Acreage Pharms to import genetics, including seed and starting material. As a result, Acreage Pharms’ already innovative and ambitious genetics breeding program is better able to offer a variety of strains that fully reflect the genetic diversity of cannabis, including its many health-enhancing properties. Once the new strains arrive at Acreage Pharms, in approximately 10 days, Acreage Pharms will begin creating and selecting specific genomes for production for medical and recreational use.
Production in the Phase 2 facility will reach 5,000 kg cannabis production per year. Phases 1 and 2 represent 40,000 square feet of growing space, and Phase 3 — which due to excellent progress on Phase 2 construction is on track for 2018 completion — will add another 80,000 square feet to Acreage Pharms canopy. The combined projects are projected to allow Acreage Pharms to produce 19,000 kg in 2018.
“Our team of plant scientists and horticultural engineers have been eagerly anticipating this exciting enlargement of our reservoir of strains,” said Kriznic. “We all remain extremely keen on offering patients and consumers a diverse suite of cannabis profiles this year.”
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on two main verticals within the Canadian cannabis sector, namely the Licensed Producers under the ACMPR, being its 100% investment in Acreage Pharms Ltd., located in West-Central Alberta, and 50% investment in AB Laboratories Inc., located near Hamilton, Ontario which has both its cultivation and sales license under ACMPR. Combined the two licenses and an expected third license under AB Ventures Inc. are expected to have an approximate annual run-rate production capacity of 76,400 kg by 2019. In addition to ACMPR licenses the Company has an 82.5% investment in Future Harvest Development Ltd. a Fertilizer and Nutrients manufacturer based in Kelowna, British Columbia.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.